The availability of weight loss drugs on the NHS doesn’t mean people can give up healthy lifestyles, Health Secretary Wes ...

Last year, Eli Lilly bought Boston-based biotech Versanis in a deal worth $1.9bn to get its hands on its muscle-preserving treatment to complement its weight-loss drugs. BioAge, a biotech with a ...

A portfolio holding that checks all these boxes is analog chip maker Texas Instruments (TXN). The company invests to build out its own manufacturing capacity, which helps make it a low-cost supplier.

John Paulson is among the most well-known billionaires, famous for his long-term investing returns via his hedge fund Paulson ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.

Get the latest news on England plans to offer Mounjaro/Zepbound to obese individuals with multiple health conditions through ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...